secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001104659-24-071261
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.
- Matthew Kaplan elected Class II director with 8,502,724 votes for, 333,228 against.
- Ratification of Kesselman & Kesselman as auditor approved: 12,055,252 for, 31,882 against.
- Voting based on 12,227,134 shares present (66.55% of outstanding) on record date April 15, 2024.
- All proposals as described in definitive proxy statement filed April 29, 2024 were approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924071261/0001104659-24-071261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924071261/tm2417208d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer